CompletedNot Applicable

Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia

Canada140 participantsStarted 2022-01-01

Plain-language summary

ACCURATE will test the hypothesis that opportunistic genetic testing for Familial Hypercholesterolemia (FH) in patients admitted to hospital with an acute coronary syndrome will increase the diagnosis of FH and will impact patient care and outcomes. The study will recruit patients admitted to hospital with an acute coronary syndrome, and research-based genetic testing will be conducted for known FH-causing genetic variants. The results will be returned to the patients' treating physicians. The primary endpoint will be the number of patients with a new diagnosis of definite FH. The secondary endpoints will be the proportion of patients who undergo intensification of lipid-lowering therapy, the lowest LDL cholesterol level achieved, and the proportion of patients reaching guideline recommended lipid targets in the 15 months after the index acute coronary syndrome.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

1. Age \<60 years AND 2. Admitted to an acute cardiac unit with either: * A ST elevation myocardial infarction (STEMI), or * A non-ST elevation myocardial infarction (NSTEMI) AND 3. Maximum lipid level at the time of admission or during the prior 1 year of * LDL level ≥4 mmol/L (154 mg/dL) if not on a statin, or * LDL-C level ≥2.5 mmol/L (96 mg/dL) if on a statin prior to presentation, or * Non-HDL-C ≥4.6 mmol/L (177 mg/dL)

What they're measuring

Number of patients with a new diagnosis of definite FH

Timeframe: 15 months

Trial details

NCT IDNCT05218005

SponsorUniversity of British Columbia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-17